Navigation Links
QLT reports initial proof of concept data for punctal plug delivery technology
Date:5/12/2008

Small study supports the potential for QLT's drug elution technology to

reduce and sustain intraocular pressure

VANCOUVER, May 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today results from a proof of concept trial conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc., of its punctal plug drug delivery technology. The results demonstrated that QLT's drug elution technology was effective in controlling intraocular pressure (IOP) and was well tolerated.

The proof of concept, open label study was initiated to determine if a sustained administration of latanoprost using the Company's punctal plug drug delivery technology could lead to a reduction in IOP over 90 days when administered using a conventional plug design. Five patients (10 eyes) with glaucoma or ocular hypertension were enrolled at a single center. The primary efficacy endpoint was measurement of IOP. At baseline, the mean IOP was 23mmHg for the 10 eyes treated. At 90 day follow-up, the mean IOP was reduced to 17mmHg for the six eyes that remained. Data from two patients were excluded due to loss of plugs. No significant adverse events were reported.

"We are very pleased to report positive results from this preliminary proof of concept trial", said Bob Butchofsky, President and Chief Executive Officer of QLT. "Although the number of patients is small, we are encouraged by the clinically meaningful reduction in IOP that was observed and sustained for approximately 90 days. We look forward to providing you with additional details from this study at our Annual General Meeting on Wednesday, May 14."

The objective of QLT's punctal plug program is to demonstrate that the Company's drug elution technology leads to a statistically significant reduction in IOP for 90 days and that its proprietary punctal plug design can be retained comfortably in a high percentage of patients during that time period. The results presented t
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Bionovo Reports First Quarter 2008 Financial Results
3. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
4. Cardium Reports on First Quarter 2008 Highlights and Financial Results
5. Novavax Reports First Quarter 2008 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
7. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
8. Pharmos Corporation Reports 2008 First Quarter Results
9. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
10. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
11. Favrille Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The fully automated supercritical fluidic ... sequentially analyze up to 48 samples utilizing automatic ... of targets by mass spectrometry. , The ... measurement requirements of a wide range of applications, ... and search for disease biomarkers, additives in forming ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... DNDN ) today announced that management will participate ... Life Sciences Conference Grand Hyatt New York ... The presentation will be audio webcast live and available ... Corporation is a biotechnology company whose mission is to,target ...
... Sept. 18 Premier Research Group plc (AIM:,PRG) ... its Vice President,Global Human Resources. Mr. Keenen will ... activities related to maximizing the,effectiveness of Premier Research,s ... strategy. Dr. Troy McCall, COO, commented: "We ...
... places Bioscrypt,s fingerprint reader on biometrics access control ... approved products list for airports, ... a,leading provider of enterprise access control technology, today announced,that its ... (TSA) and placed on the TSA,s "Biometrics for,Access Control" Qualified ...
Cached Biology Technology:Premier Research Appoints Global Head of Human Resources 2Bioscrypt's V-Station MIFARE Placed on Transportation Security Administration's Qualified Products List 2Bioscrypt's V-Station MIFARE Placed on Transportation Security Administration's Qualified Products List 3
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/9/2015)... 2015  Lintec of America recently announced an exclusive ... (CNT) macrostructures, including sheets, yarns and ribbons, developed at ... Leveraging the vast industrial resources of the global Lintec ... Lintec of America is forming the Nano-Science and Technology ... focusing on scaling up the manufacturing and commercialization of ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... A test for the two strains of human papillomavirus responsible ... molecular assay uses a cervical scraping, like that for a ... 18, responsible for 70 percent of cervical cancers, says Dr. ... Gynecologic Cancer Prevention Center at the Medical College of Georgia. ...
... the world’s 162 species of grouper, a culinary favorite ... with extinction unless proper management or conservation measures are ... Conservation Union (IUCN) as under extinction threat, and the ... of 20 experts from 10 nations determined the extinction ...
... way primitive yeast make cholesterol, a team of ... counterpart controls cholesterol production and potentially drug metabolism. ... Hopkins University School of Medicine, Vanderbilt University, Indiana ... the February issue of Cell Metabolism. ...
Cached Biology News:New test for most virulent HPV strains under study 2New test for most virulent HPV strains under study 3Twenty of world's 162 grouper species threatened with extinction 2Primitive yeast yields secrets of human cholesterol and drug metabolism 2
... ChemiLucent™ Plus is a chemiluminescent ... used independently to boost the signal ... blot detection kits. ChemiLucent™ Plus is ... technology. Unlike conjugated complex- or chemiluminescent ...
... for proteomic scale kinase profiling, quantitative ... drug discovery research built on the ... synthesis platform. These microarrays are available ... Kinase Substrate - Peptide Microarray Service. ...
... Imaging System, Basic Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
... time, you can identify and characterize high-value, ... interferences. The Agilent Multiple Affinity Removal System ... proteins from human serum, plasma, CSF samples ... With this revolutionary system, you can: ...
Biology Products: